EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (AMEX:AIS) today announced that the Company has received a $1.75 million milestone payment of $2.6 million due in 2007 from Bradley Pharmaceuticals Inc. (NYSE:BDY). The milestone was received pursuant to a marketing agreement Bradley signed with Biosante Pharmaceuticals (a licensee of Antares) for the product Elestrin™, a low dose transdermal estradiol therapy delivered in our proprietary Advanced Transdermal Delivery (ATD™) gel system for the treatment of hot flashes in menopausal women. Additional regulatory and sales based milestone payments could bring the total of such payments to Antares to more than $13 million. Antares will also receive an important portion of the royalties on third party sales of Elestrin as well.
